Even Fierce Biotech says ANOTHER revised protocol had been submitted AFTER the January 2024 resubmission---
Date of article Feb 29, 2024 10:20am
Earlier this month, CytoDyn finally submitted a revised protocol for the HIV trial, which again had little detail on the nature of the FDA's concern. Lalezari, who officially ascended to the CEO role in January, was confident that the amendment would finally convince the FDA to lift the hold. https://www.fiercebiotech.com/biotech/cytodyn-finally-clears-fda-hold-hiv-program-after-two-years